Anavex Life Sciences 미래 성장
Future 기준 확인 3/6
Anavex Life Sciences은 연간 수입과 매출이 각각 47.7%와 52.4% 증가할 것으로 예상되고 EPS는 연간 52.3%만큼 증가할 것으로 예상됩니다.
주요 정보
47.7%
수익 성장률
52.3%
EPS 성장률
| Biotechs 수익 성장 | 28.3% |
| 매출 성장률 | 52.4% |
| 향후 자기자본 수익률 | n/a |
| 애널리스트 커버리지 | Low |
| 마지막 업데이트 | 04 Nov 2024 |
최근 미래 성장 업데이트
Recent updates
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Nov 11Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16수익 및 매출 성장 예측
| 날짜 | 수익 | 수익 | 잉여 현금 흐름 | 작전 현금 | 평균 애널리스트 수 |
|---|---|---|---|---|---|
| 9/30/2027 | 630 | 402 | 822 | 610 | 2 |
| 9/30/2026 | 390 | 481 | 542 | 738 | 2 |
| 9/30/2025 | N/A | 80 | -60 | 222 | 3 |
| 9/30/2024 | N/A | -46 | -58 | -39 | 3 |
| 6/30/2024 | N/A | -42 | -30 | -30 | N/A |
| 3/31/2024 | N/A | -41 | -32 | -32 | N/A |
| 12/31/2023 | N/A | -43 | -29 | -29 | N/A |
| 9/30/2023 | N/A | -48 | -28 | -28 | N/A |
| 6/30/2023 | N/A | -52 | -26 | -26 | N/A |
| 3/31/2023 | N/A | -53 | -25 | -25 | N/A |
| 12/31/2022 | N/A | -50 | -27 | -27 | N/A |
| 9/30/2022 | N/A | -48 | -24 | -24 | N/A |
| 6/30/2022 | N/A | -45 | -28 | -28 | N/A |
| 3/31/2022 | N/A | -43 | -28 | -28 | N/A |
| 12/31/2021 | N/A | -41 | -26 | -26 | N/A |
| 9/30/2021 | N/A | -38 | -30 | -30 | N/A |
| 6/30/2021 | N/A | -32 | -29 | -29 | N/A |
| 3/31/2021 | N/A | -28 | -25 | -25 | N/A |
| 12/31/2020 | N/A | -28 | -23 | -23 | N/A |
| 9/30/2020 | N/A | -26 | -21 | -21 | N/A |
| 6/30/2020 | N/A | -26 | -18 | -18 | N/A |
| 3/31/2020 | N/A | -26 | -21 | -21 | N/A |
| 12/31/2019 | N/A | -26 | -20 | -20 | N/A |
| 9/30/2019 | N/A | -26 | -19 | -19 | N/A |
| 6/30/2019 | N/A | -26 | -20 | -20 | N/A |
| 3/31/2019 | N/A | -23 | -15 | -15 | N/A |
| 12/31/2018 | N/A | -20 | -13 | -13 | N/A |
| 9/30/2018 | N/A | -17 | -13 | -13 | N/A |
| 6/30/2018 | N/A | -17 | -11 | -11 | N/A |
| 3/31/2018 | N/A | -18 | N/A | -12 | N/A |
| 12/31/2017 | N/A | -14 | N/A | -9 | N/A |
| 9/30/2017 | N/A | -13 | N/A | -9 | N/A |
| 6/30/2017 | N/A | -15 | N/A | -9 | N/A |
| 3/31/2017 | N/A | -13 | N/A | -8 | N/A |
| 12/31/2016 | N/A | -14 | N/A | -9 | N/A |
| 9/30/2016 | N/A | -15 | N/A | -9 | N/A |
| 6/30/2016 | N/A | -14 | N/A | -9 | N/A |
| 3/31/2016 | N/A | -16 | N/A | -8 | N/A |
| 12/31/2015 | N/A | -15 | N/A | -7 | N/A |
| 9/30/2015 | N/A | -12 | N/A | -4 | N/A |
| 6/30/2015 | N/A | -15 | N/A | -4 | N/A |
| 3/31/2015 | N/A | -12 | N/A | -3 | N/A |
| 12/31/2014 | N/A | -11 | N/A | -3 | N/A |
| 9/30/2014 | N/A | -10 | N/A | -3 | N/A |
| 6/30/2014 | N/A | -5 | N/A | -2 | N/A |
| 3/31/2014 | N/A | -4 | N/A | -1 | N/A |
애널리스트 미래 성장 예측
수입 대 저축률: AVXL 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 2.6% )보다 빠른 성장으로 간주됩니다.
수익 vs 시장: AVXL (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.
고성장 수익: AVXL 향후 3년 내에 수익을 낼 것으로 예상됩니다.
수익 대 시장: AVXL 은(는) 내년에 수익이 없을 것으로 예상됩니다.
고성장 수익: AVXL 은(는) 내년에 수익이 없을 것으로 예상됩니다.
주당 순이익 성장 예측
미래 자기자본 수익률
미래 ROE: AVXL 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.